Corporate Snapshot: Guangzhou Kingmed Diagnostics (603882.SS)
Guangzhou Kingmed Diagnostics, a listed entity on the Shanghai Stock Exchange, completed a 24‑hour trading cycle on Friday, 23 November 2026, with its share price unchanged, reflecting a flat 0 % movement at 10:42 PM Central Europe. The most recent trading price on major exchanges is approximately CNY 30.60 per share.
Market Overview
- Outstanding Shares: 463.3 million
- Current Market Capitalisation: CNY 2 billion
- 24‑Hour Turnover: CNY 435.1 million worth of shares were exchanged over the past day.
- Performance Since End of Last Month: The stock has risen by 3.61 % relative to the preceding month‑end level.
- Simple Moving Average (200 days): CNY 26.91, indicating a moderate upward trend.
- 52‑Week Range: The highest recorded price, CNY 40.68, was achieved on 13 January 2026, while the lowest, CNY 21.50, fell on 29 June 2026.
Peer Activity in the 24‑Hour Window
| Ticker | Trade Status | Current Price | Market Cap (CNY bn) | P/E Ratio | Additional Notes |
|---|---|---|---|---|---|
| HIG (000548.SZ) | Flat 0 % | CNY 4.35 | 2.2 | 70.47 | Parent company HONG RIDA has recently established a wholly‑owned subsidiary in Hunan focusing on additive manufacturing equipment and services. |
| Lian (300784.SZ) | Flat 0 % | CNY 39.42 | 2.2 | – | – |
| Huaqitech (300929.SZ) | Flat 0 % | CNY 15.47 | 2.2 | – | – |
| Weihai Baihe Biology Technological (603102.SS) | Flat 0 % | CNY 35.10 | 2.2 | 19.31 | – |
| Double Arrow (002381.SZ) | Flat 0 % | CNY 5.32 | 2.2 | 57.47 | – |
All peer stocks exhibited no price movement over the same 24‑hour period, underscoring a broader period of market stability among these mid‑cap Chinese equities.
Business Context
Guangzhou Kingmed Diagnostics Group Co., Ltd. is a prominent medical laboratory headquartered in Guangzhou. Its core operations encompass clinical testing, pathology diagnosis outsourcing, and related services supplied to a diverse clientele that includes hospitals, maternity and child health centers, health centers, and other medical facilities. The company’s services are pivotal to the diagnostic infrastructure of the region, providing critical data that informs patient care and clinical decision‑making.
The firm’s corporate website, www.kingmed.com.cn , offers further insight into its service portfolio and operational footprint. As a public company listed on the Shanghai Stock Exchange, Guangzhou Kingmed Diagnostics remains subject to the rigorous disclosure and regulatory requirements that govern Chinese listed entities.
Conclusion
Despite a lack of price fluctuation in the most recent trading session, Guangzhou Kingmed Diagnostics maintains a solid market position with a healthy share of liquidity and a stable valuation relative to its 200‑day moving average. The company’s continued focus on delivering essential diagnostic services positions it to benefit from ongoing demand for quality medical testing in China’s evolving healthcare landscape.
